This work has culminated in computational models of NF-κB signalling that integrate the main components that are commonly dysregulated in poor prognosis DLBCL patients (e.g. CD79B and CARD11 within BCR signalling, MYD88 within TLR signalling, and NFKBIE and TNFAIP3 within core negative regulation of NF-κB) [60,61]. The gene discussed is NFKB1; the disease is diffuse large B-cell lymphoma.